Abstract 354P
Background
In Malaysia, up to 68% of cancer patients uses CAM, with CAM disclosure at only 7.6%. Perception of doctors’ poor knowledge on CAM, and non-belief in its practice are some reasons cited for non-disclosure. This may lead to various complications.
Methods
This cross-sectional study was carried out in 2 university hospitals in Malaysia from 1st July to 23rd December 2016. All doctors and nurses of Oncology Departments were included. Subjects were briefed on the study before questionnaires were distributed and returned anonymously once completed. The questionnaire was adopted with local adaptations, from a study done in Japan on perceptions and attitudes on CAM. A pilot study was done and the final validated version consists of 2 sections. Section A consists of questions on socio-demographic characteristics of respondent. Section B consisted of questions to assess the respondent’s knowledge, perception and attitude on CAM. Each question was given a point scale. Based on total points obtained, respondents were classified into good or poor knowledge, positive or negative perception and attitude towards CAM.
Results
Total of 60 nurses and 26 doctors responded, with 16 male and 70 female. Generally, all respondents have poor knowledge on CAM. Two thirds (67.4%) were not aware of the existence of the National Policy on CAM in Malaysia. Most have very little or no knowledge on the CAM modalities listed. The respondents have negative perception on CAM, with 83.7% feel the lack of evidence in its effectiveness. Most (72%) think that there is a definite or possible interaction between CAM products and anticancer drugs. All have negative attitude on CAM except 8.1% of respondents encouraging the use of CAM. Majority do not encourage the use of CAM products in both early (79.1%) and advanced (64%) stage.
Conclusions
Oncology-related healthcare providers have poor knowledge, with negative perception and attitude towards CAM.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
61P - Clinical implication of BRCA mutation in breast cancer with central nervous system metastasis
Presenter: Jwa Hoon Kim
Session: e-Poster Display Session
62P - IGF axis in breast cancer recurrence and metastasis
Presenter: Hajara Akhter
Session: e-Poster Display Session
63P - Butterfly pea (<italic>Clitoria ternatea</italic> Linn.) flower extract prevents MCF-7 HER2-positive breast cancer cell metastasis in-vitro
Presenter: Azzahra Asysyifa
Session: e-Poster Display Session
64P - Pre-treatment absolute white blood cell profile count as metastatic predictive factors in invasive ductal carcinoma breast cancer
Presenter: Wikania I Gede
Session: e-Poster Display Session
65P - The new mouse anti-nNav1.5 monoclonal antibody
Presenter: Nur Aishah Sharudin
Session: e-Poster Display Session
66P - The TILs near solid structures is a potential prognostic factor of distant metastases in the luminal HER2-negative breast cancer
Presenter: Vladimir Alifanov
Session: e-Poster Display Session
73P - Selinexor in combination with carboplatin and pemetrexed (CP) in patients with advanced or metastatic solid tumors: Results of an open label, single-center, multi-arm phase Ib study
Presenter: Kyaw Thein
Session: e-Poster Display Session
74P - Comprehensive transcriptome analysis of endoplasmic reticulum stress in osteosarcomas
Presenter: Yoshiyuki Suehara
Session: e-Poster Display Session
75P - The evaluation of selective sensitivity of EZH2 inhibitors based on synthetic lethality in ARID1A-deficient gastric cancer
Presenter: Leo Yamada
Session: e-Poster Display Session
76P - Targeted tumour photoImmunotherapy against triple-negative breast cancer therapy
Presenter: Vivek Raju
Session: e-Poster Display Session